In brief: CSL, Progen Industries, Mayne Group
Tuesday, 28 June, 2005
CSL (ASX:CSL) will be conducting a further on-market buyback of up to 8 million shares during a 12-month period commencing July 12. "Combined with the buyback completed in May of this year it is likely that we will have returned to shareholders in excess of the AUD$550 million we raised to acquire the global plasma therapeutics business of Aventis Behring in December 2004. At the same time the market value for CSL has more than doubled since making the announcement to acquire the business," said CSL managing director Brian McNamee in a statement.
Progen Industries (ASX:PGL; NASDAQ:PGLAF) has engaged San Francisco-based global life sciences merchant bank Burrill & Company to accelerate a partnering transaction for the company's lead anti-cancer product PI-88. Progen's vice president business development Darren Schliebs has resigned.
Mayne Group (ASX:MAY) has appointed Nora Scheinkestel as a non-executive director effective July 1.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
